Literature DB >> 17553898

Heterologous prime/boost immunization of rhesus monkeys by using diverse poxvirus vectors.

Sampa Santra1, Yue Sun, Jenny G Parvani, Valerie Philippon, Michael S Wyand, Kelledy Manson, Alicia Gomez-Yafal, Gail Mazzara, Dennis Panicali, Phillip D Markham, David C Montefiori, Norman L Letvin.   

Abstract

As the diversity of potential immunogens increases within certain classes of vectors, the possibility has arisen of employing heterologous prime/boost immunizations using diverse members of the same family of vectors. The present study was initiated to explore the use of divergent pox vectors in a prime/boost regimen to elicit high-frequency cellular immune responses to human immunodeficiency virus type 1 envelope and simian immunodeficiency virus gag in rhesus monkeys. We demonstrated that monkeys vaccinated with a recombinant modified vaccinia virus Ankara (rMVA) prime/recombinant fowlpox virus (rFPV) boost regimen and monkeys vaccinated with a recombinant vaccinia virus prime/rFPV boost regimen developed comparable cellular immune responses that were greater in magnitude than those elicited by a homologous prime/boost with rMVA. Nevertheless, comparable magnitude recall cellular immune responses were observed in monkeys vaccinated with heterologous and homologous recombinant poxvirus following challenge with the CXCR4-tropic SHIV-89.6P. Consistent with this finding, comparable levels of containment of viral replication and CD4(+) T-lymphocyte preservation were seen in these groups of recombinant poxvirus-vaccinated monkeys. This study supports further exploration of combining recombinant vectors of the same family in prime/boost immunization strategies to optimize vaccine-elicited cellular immune responses.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17553898      PMCID: PMC1951337          DOI: 10.1128/JVI.00744-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

1.  Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination.

Authors:  D H Barouch; S Santra; J E Schmitz; M J Kuroda; T M Fu; W Wagner; M Bilska; A Craiu; X X Zheng; G R Krivulka; K Beaudry; M A Lifton; C E Nickerson; W L Trigona; K Punt; D C Freed; L Guan; S Dubey; D Casimiro; A Simon; M E Davies; M Chastain; T B Strom; R S Gelman; D C Montefiori; M G Lewis; E A Emini; J W Shiver; N L Letvin
Journal:  Science       Date:  2000-10-20       Impact factor: 47.728

2.  An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants.

Authors:  N F Rose; P A Marx; A Luckay; D F Nixon; W J Moretto; S M Donahoe; D Montefiori; A Roberts; L Buonocore; J K Rose
Journal:  Cell       Date:  2001-09-07       Impact factor: 41.582

3.  Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

Authors:  R R Amara; F Villinger; J D Altman; S L Lydy; S P O'Neil; S I Staprans; D C Montefiori; Y Xu; J G Herndon; L S Wyatt; M A Candido; N L Kozyr; P L Earl; J M Smith; H L Ma; B D Grimm; M L Hulsey; J Miller; H M McClure; J M McNicholl; B Moss; H L Robinson
Journal:  Science       Date:  2001-04-06       Impact factor: 47.728

4.  Virus-specific cellular immune correlates of survival in vaccinated monkeys after simian immunodeficiency virus challenge.

Authors:  Yue Sun; Jörn E Schmitz; Adam P Buzby; Brianne R Barker; Srinivas S Rao; Ling Xu; Zhi-Yong Yang; John R Mascola; Gary J Nabel; Norman L Letvin
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

5.  Subdominant CD8+ T-cell responses are involved in durable control of AIDS virus replication.

Authors:  Thomas C Friedrich; Laura E Valentine; Levi J Yant; Eva G Rakasz; Shari M Piaskowski; Jessica R Furlott; Kimberly L Weisgrau; Benjamin Burwitz; Gemma E May; Enrique J León; Taeko Soma; Gnankang Napoe; Saverio V Capuano; Nancy A Wilson; David I Watkins
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

6.  Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag.

Authors:  Danilo R Casimiro; Fubao Wang; William A Schleif; Xiaoping Liang; Zhi-Qiang Zhang; Timothy W Tobery; Mary-Ellen Davies; Adrian B McDermott; David H O'Connor; Arthur Fridman; Ansu Bagchi; Lynda G Tussey; Andrew J Bett; Adam C Finnefrock; Tong-ming Fu; Aimin Tang; Keith A Wilson; Minchun Chen; Helen C Perry; Gwendolyn J Heidecker; Daniel C Freed; Anthony Carella; Kara S Punt; Kara J Sykes; Lingyi Huang; Virginia I Ausensi; Margaret Bachinsky; Usha Sadasivan-Nair; David I Watkins; Emilio A Emini; John W Shiver
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

7.  Molecularly cloned SHIV-1157ipd3N4: a highly replication- competent, mucosally transmissible R5 simian-human immunodeficiency virus encoding HIV clade C Env.

Authors:  R J Song; A-L Chenine; R A Rasmussen; C R Ruprecht; S Mirshahidi; R D Grisson; W Xu; J B Whitney; L M Goins; H Ong; P-L Li; E Shai-Kobiler; T Wang; C M McCann; H Zhang; C Wood; C Kankasa; W E Secor; H M McClure; E Strobert; J G Else; R M Ruprecht
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

8.  Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys.

Authors:  Anjali Nanda; Diana M Lynch; Jaap Goudsmit; Angelique A C Lemckert; Bonnie A Ewald; Shawn M Sumida; Diana M Truitt; Peter Abbink; Michael G Kishko; Darci A Gorgone; Michelle A Lifton; Ling Shen; Angela Carville; Keith G Mansfield; Menzo J E Havenga; Dan H Barouch
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

Review 9.  Applications of pox virus vectors to vaccination: an update.

Authors:  E Paoletti
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

10.  Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys.

Authors:  Norman L Letvin; John R Mascola; Yue Sun; Darci A Gorgone; Adam P Buzby; Ling Xu; Zhi-Yong Yang; Bimal Chakrabarti; Srinivas S Rao; Jörn E Schmitz; David C Montefiori; Brianne R Barker; Fred L Bookstein; Gary J Nabel
Journal:  Science       Date:  2006-06-09       Impact factor: 47.728

View more
  26 in total

Review 1.  Enhancing poxvirus vectors vaccine immunogenicity.

Authors:  Juan García-Arriaza; Mariano Esteban
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 2.  Poxvirus vectors as HIV/AIDS vaccines in humans.

Authors:  Carmen Elena Gómez; Beatriz Perdiguero; Juan Garcia-Arriaza; Mariano Esteban
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

3.  Impact of anti-orthopoxvirus neutralizing antibodies induced by a heterologous prime-boost HIV-1 vaccine on insert-specific immune responses.

Authors:  Stephen R Walsh; Michael S Seaman; Lauren E Grandpre; Cherie Charbonneau; Katherine E Yanosick; Barbara Metch; Michael C Keefer; Raphael Dolin; Lindsey R Baden
Journal:  Vaccine       Date:  2012-11-07       Impact factor: 3.641

4.  Vaccination reduces simian-human immunodeficiency virus sequence reversion through enhanced viral control.

Authors:  Edwin R Manuel; Wendy W Yeh; Harikrishnan Balachandran; Ryon H Clarke; Michelle A Lifton; Norman L Letvin
Journal:  J Virol       Date:  2010-09-29       Impact factor: 5.103

5.  Use of mchI encoding immunity to the antimicrobial peptide microcin H47 as a plasmid selection marker in attenuated bacterial live vectors.

Authors:  Chee-Mun Fang; Jin Yuan Wang; Magaly Chinchilla; Myron M Levine; William C Blackwelder; James E Galen
Journal:  Infect Immun       Date:  2008-07-28       Impact factor: 3.441

6.  Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials.

Authors:  Scott A Brown; Sherri L Surman; Robert Sealy; Bart G Jones; Karen S Slobod; Kristen Branum; Timothy D Lockey; Nanna Howlett; Pamela Freiden; Patricia Flynn; Julia L Hurwitz
Journal:  Viruses       Date:  2010-02-01       Impact factor: 5.048

7.  Prime-boost vaccination with recombinant mumps virus and recombinant vesicular stomatitis virus vectors elicits an enhanced human immunodeficiency virus type 1 Gag-specific cellular immune response in rhesus macaques.

Authors:  R Xu; F Nasar; S Megati; A Luckay; M Lee; S A Udem; J H Eldridge; M A Egan; E Emini; D K Clarke
Journal:  J Virol       Date:  2009-07-22       Impact factor: 5.103

Review 8.  Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development.

Authors:  L Jean Patterson; Marjorie Robert-Guroff
Journal:  Expert Opin Biol Ther       Date:  2008-09       Impact factor: 4.388

9.  Magnitude and quality of vaccine-elicited T-cell responses in the control of immunodeficiency virus replication in rhesus monkeys.

Authors:  Yue Sun; Sampa Santra; Jörn E Schmitz; Mario Roederer; Norman L Letvin
Journal:  J Virol       Date:  2008-06-25       Impact factor: 5.103

10.  Enhancement of the expression of HCV core gene does not enhance core-specific immune response in DNA immunization: advantages of the heterologous DNA prime, protein boost immunization regimen.

Authors:  Ekaterina Alekseeva; Irina Sominskaya; Dace Skrastina; Irina Egorova; Elizaveta Starodubova; Eriks Kushners; Marija Mihailova; Natalia Petrakova; Ruta Bruvere; Tatyana Kozlovskaya; Maria Isaguliants; Paul Pumpens
Journal:  Genet Vaccines Ther       Date:  2009-06-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.